Skip to main content
SpringerLink
Log in
Book cover

Applications of Antisense Therapies to Restenosis pp 1–19Cite as

Restenosis: The Clinical Problem

  • Chapter

  • 43 Accesses

Part of the book series: Perspectives in Antisense Science ((DARE,volume 3))

Abstract

Since its introduction(1) in 1977, percutaneous transluminal coronary angioplasty (PTCA) has become accepted as a safe and effective alternative to medical therapy for the treatment of limited coronary artery disease(2), as well as an alternative to coronary artery bypass grafting (CABG) for the treatment of more extensive coronary atherosclerosis(3, 4). The success of PTCA as a method of coronary revascularization has contributed to its explosive growth, with approximately 500,000 procedures performed per year in the United States.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilation of coronary artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979; 301:61–68.

    PubMed  CAS  Google Scholar 

  2. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators [see comments]. N Engl J Med. 1992; 326:10–16.

    PubMed  CAS  Google Scholar 

  3. The BARI Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 1996; 335:217–225.

    Google Scholar 

  4. King SBr, Lembo NJ, Weintraub WS, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST) [see comments]. N Engl J Med. 1994; 331:1044–1050.

    PubMed  Google Scholar 

  5. Faxon DP, Spiro TE, Minor S, et al. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial. Circulation. 1994; 90:908–914.

    PubMed  CAS  Google Scholar 

  6. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group [see comments]. N Engl J Med. 1994; 331:489–495.

    PubMed  CAS  Google Scholar 

  7. Fischman DL, Leon MB, Bairn DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators [see comments]. N Engl J Med. 1994; 331:496–501.

    PubMed  CAS  Google Scholar 

  8. Wiedermann JG, Marboe C, Amols H, et al. Intracoronary irradiation markedly reduces restenosis after balloon angioplasty in a porcine model. J Am Coll Cardiol. 1994; 23:1491–1498.

    PubMed  CAS  Google Scholar 

  9. Kuntz RE, Gibson CM, Nobuyoshi M, et al. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J Am Coll Cardiol. 1993; 21:15–25.

    PubMed  CAS  Google Scholar 

  10. Waksman R, Robinson KA, Crocker IR, et al. Endovascular low-dose irradiation inhibits neointima formation after coronary artery balloon injury in swine. A possible role for radiation therapy in restenosis prevention. Circulation. 1995; 91:1533–1539.

    PubMed  CAS  Google Scholar 

  11. Kimura T, Nosaka H, Yokoi H, et al. Serial angiographic follow-up after Palmaz-Schatz stent implantation: comparison with conventional balloon angioplasty. J Am Coll Cardiol. 1993; 21:1557–1563.

    PubMed  CAS  Google Scholar 

  12. Di Mario C, Gil R, Camenzind E, et al. Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy. Am J Cardiol. 1995; 75:772–777.

    PubMed  Google Scholar 

  13. Marie PY, Danchin N, Karcher G, et al. Usefulness of exercise SPECT-thallium to detect asymptomatic restenosis in patients who had angina before coronary angioplasty. Am Heart Journal. 1993; 126:571–577.

    CAS  Google Scholar 

  14. Bengtson JR, Mark DB, Honan MB, et al. Detection of restenosis after elective percutaneous transluminal coronary angioplasty using the exercise treadmill test. Am J Cardiol. 1990; 65:28–34.

    PubMed  CAS  Google Scholar 

  15. Klein LW, Avula SB, Uretz E, et al. Utility of various clinical, noninvasive, and invasive procedures for determining the causes of recurrence of myocardial ischemia or infarction or = 1 year after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1995; 75:1003–1006.

    PubMed  CAS  Google Scholar 

  16. Danchin N, Juilliere Y, Foley D, et al. Visual versus quantitative assessment of the severity of coronary artery stenoses: can the angiographer’s eye be reeducated? Am Heart Journal. 1993; 126:594–600.

    CAS  Google Scholar 

  17. Mintz GS, Popma JJ, Hong MK, et al. Intravascular ultrasound to discern device-specific effects and mechanisms of restenosis. Am J Cardiol. 1996; 78:18–22.

    PubMed  CAS  Google Scholar 

  18. Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 1996; 94:35–43.

    PubMed  CAS  Google Scholar 

  19. Mintz GS, Popma JJ, Pichard AD, et al. Intravascular ultrasound predictors of restenosis after percutaneous transcatheter coronary revascularization. J Am Coll Cardiol. 1996; 27:1678–1687.

    PubMed  CAS  Google Scholar 

  20. Savage MP, Goldberg S, Bove AA, et al. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II) [see comments]. Circulation. 1995; 92:3194–3200.

    PubMed  CAS  Google Scholar 

  21. Topol EJ, Leya F, Pinkerton CA, et al. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group [see comments]. N Engl J Med. 1993; 329:221–227.

    CAS  Google Scholar 

  22. Sheikh KH, Bengtson JR, Helmy S, et al. Relation of quantitative coronary lesion measurements to the development of exercise- induced ischemia assessed by exercise echocardiography [see comments]. J Am Coll Cardiol. 1990; 15:1043–1051.

    PubMed  CAS  Google Scholar 

  23. Hillegass WB, Ohman EM, Califf RM. Restenosis: The Clinical Issues. In: Topol EJ, ed. Textbook of Interventional Cardiology. Philadelphia: Saunders:415–435.

    Google Scholar 

  24. Holmes DR, Jr., Vlietstra RE, Smith HC, et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol. 1984; 53:77C–81C.

    PubMed  Google Scholar 

  25. Hillegass WB, Bengtson JR, Ancukiewicz M, et al. Pre-discharge exercise testing does not predict clinical events or restenosis after successful angioplasty. Circulation. 1992; 86 (suppl I):1–137.

    Google Scholar 

  26. Van Tosh A, Garza D, Roberti R, et al. Serial myocardial perfusion imaging with dipyridamole and rubidium-82 to assess restenosis after angioplasty. Journal of Nuclear Medicine. 1995; 36:1553–1560.

    PubMed  Google Scholar 

  27. Flachskampf FA, Hoffmann R, vom Dahl J, et al. Functional assessment of PTCA results by stress echocardiography: when and how to test. Eur Heart Journal. 1995; 16:31–34.

    Google Scholar 

  28. Hoffmann R, Lethen H, Flachskampf FA, et al. Exercise echocardiography performed early and late after percutaneous transluminal coronary angioplasty for prediction of restenosis. Eur Heart Journal. 1995; 16:1872–1879.

    CAS  Google Scholar 

  29. Hlatky MA, Rogers WJ, Johnstone I, et al. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators [see comments]. N Engl J Med. 1997; 336:92–99.

    PubMed  CAS  Google Scholar 

  30. de Groote P, Bauters C, McFadden EP, et al. Local lesion-related factors and restenosis after coronary angioplasty. Evidence from a quantitative angiographic study in patients with unstable angina undergoing double-vessel angioplasty. Circulation. 1995; 91:968–972.

    PubMed  Google Scholar 

  31. Fuster V. Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology [published erratum appears in Circulation 1995 Jan 1;91(1):256]. Circulation. 1994; 90:2126–2146.

    PubMed  CAS  Google Scholar 

  32. Bauters C, Lablanche JM, McFadden EP, et al. Relation of coronary angioscopic findings at coronary angioplasty to angiographic restenosis. Circulation. 1995; 92:2473–2479.

    PubMed  CAS  Google Scholar 

  33. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol. 1989; 135:169–175.

    PubMed  CAS  Google Scholar 

  34. Biasucci LN, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina. Circulation. 1996; 95:874–877.

    Google Scholar 

  35. Yazdani S, Simon AD, Wang W, et al. Inflammatory profile in unstable angina vs. stable angina in patients undergoing percutaneous interventions. Am Heart Journal. 1998; In press.

    Google Scholar 

  36. Simon AD, Yazdani S, Wang W, et al. Inflammatory cytokine profiles in stable versus unstable angina (abstract). J Am Coll Cardiol. 1998; 29:233A.

    Google Scholar 

  37. Komowski R, Hong MK, Tio FO, et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998; 31:224–230.

    Google Scholar 

  38. Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation. 1995; 91:979–989.

    PubMed  CAS  Google Scholar 

  39. Klugherz BD, DeAngelo DL, Kim BK, et al. Three-year clinical follow-up after Palmaz-Schatz stenting. J Am Coll Cardiol. 1996; 27:1185–1191.

    PubMed  CAS  Google Scholar 

  40. Levine GN, Jacobs AK, Keeler GP, et al. Impact of diabetes mellitus on percutaneous revascularization (CAVEAT-I). CAVEAT-I Investigators. Coronary Angioplasty Versus Excisional Atherectomy Trial. Am J Cardiol. 1997; 79:748–755.

    PubMed  CAS  Google Scholar 

  41. Warth DC, Leon MB, O’Neill W, et al. Rotational atherectomy multicenter registry: acute results, complications and 6-month angiographic follow-up in 709 patients. J Am Coll Cardiol. 1994; 24:641–648.

    PubMed  CAS  Google Scholar 

  42. Rabbani LE, Edelman ER, Ganz P, et al. Relation of restenosis after excimer laser angioplasty to fasting insulin levels. Am J Cardiol. 1994; 73:323–327.

    PubMed  CAS  Google Scholar 

  43. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol. 1996; 27:528–535.

    PubMed  CAS  Google Scholar 

  44. Montalescot G, Ankri A, Vicaut E, et al. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation. 1995; 92:31–38.

    PubMed  CAS  Google Scholar 

  45. Ishiwata S, Tukada T, Nakanishi S, et al. Postangioplasty restenosis: platelet activation and the coagulation- fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart Journal. 1997; 133:387–392.

    CAS  Google Scholar 

  46. Yazdani S, Simon AD, Kovar L, et al. Percutaneous interventions alter the hemostatic profile in patients with unstable versus stable angina. J Am Coll Cardiol. 1997; 30:1284–1287.

    PubMed  CAS  Google Scholar 

  47. Bergelson BA, Jacobs AK, Small DM. Lipoproteias predict restenosis after PTCA. Circulation. 1989; 80(suppl II):II-65.

    Google Scholar 

  48. Horie H, Takahashi M, Izumi M, et al. Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty. Circulation. 1997; 96:166–173.

    PubMed  CAS  Google Scholar 

  49. Desmarais RL, Sarembock IJ, Ayers CR, et al. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty [see comments]. Circulation. 1995; 91:1403–1409.

    PubMed  CAS  Google Scholar 

  50. Violaris AG, Melkert R, Serruys PW. Influence of serum cholesterol and cholesterol subfractions on restenosis after successful coronary angioplasty. A quantitative angiographic analysis of 3336 lesions. Circulation. 1994; 90:2267–2279.

    PubMed  CAS  Google Scholar 

  51. Weintraub WS, Boccuzzi SJ, Klein JL, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. N Engl J Med. 1994; 331:1331–1337.

    PubMed  CAS  Google Scholar 

  52. O’Keefe JH, Jr., Stone GW, McCallister BD, Jr., et al. Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1996; 77:649–652.

    PubMed  Google Scholar 

  53. Watanabe K, Sekiya M, Ikeda S, et al. Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am Heart Journal. 1996; 132:23–29.

    CAS  Google Scholar 

  54. Halon DA, Merdier A, Shefer A, et al. Identifying patients at high risk for restenosis after percutaneous transluminal coronary angioplasty for unstable angina pectoris. Am J Cardiol. 1989; 64:289–293.

    PubMed  CAS  Google Scholar 

  55. Hirshfeld JW, Schwartz JS, Jugo R, et al. Restenosis after coronary angioplasty: a multivariate statistical model to relate lesions and procedure variables to restenosis. J Am Coll Cardiol. 1991; 18:647–656.

    PubMed  Google Scholar 

  56. Liu MW, Roubin GS, King SBr. Effect of angiographic and hemodynamic results of coronary balloon angioplasty on late angiographic outcome. Am Heart Journal. 1994; 128:1077–1083.

    CAS  Google Scholar 

  57. Barnathan JS, Schwartz JS, Taylor L. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation. 1987; 76:125–134.

    PubMed  CAS  Google Scholar 

  58. Schwartz L, Bourassa MG, Lesperance J. Aspirin and dyipyridamole in the prevention of restenosis after percutaneous coronary angioplasty. N Engl J Med. 1988; 318:1714–1719.

    PubMed  CAS  Google Scholar 

  59. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance [see comments]. Circulation. 1995; 91:1676–1688.

    PubMed  CAS  Google Scholar 

  60. Bellavance A. Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events. The Ticlopidine Aspirin Stroke Study [see comments]. Stroke. 1993; 24:1452–1457.

    PubMed  CAS  Google Scholar 

  61. Bertrand ND, Allain H, Lablanche J. Results of a randomized trial of ticlopidine versus placebo for the prevention of acute closure and restenosis after coronary angioplasty (PTCA): the TACT study (abstr). Circulation. 1990; 82:111–190.

    Google Scholar 

  62. Gershlick AH, Spriggins D, Davies SW, et al. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial. BMJ. 1994; 71:7–15.

    CAS  Google Scholar 

  63. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators [see comments]. Lancet. 1994; 343:881–886.

    PubMed  CAS  Google Scholar 

  64. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation [see comments]. N Engl J Med. 1994; 330:956–961.

    Google Scholar 

  65. The IMPACT II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary interventions: IMPACT-II. Lancet. 1997; 349:1422–1428.

    Google Scholar 

  66. Kereiakes DJ, Kleiman NS, J. A. Randomized, double-blind, placebo-controlled dose-ranging study of Tirofiban (MK-383) platelet IIb/IIIa blockade in high-risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 1996; 27:536–542.

    PubMed  CAS  Google Scholar 

  67. EPILOG Investigators. Effect of the platelet glycoprotein IIb/IIa receptor inhibitor abciximab with lower heparin dosages on ischemic complications of percutaneous coronary revascularization. N Engl J Med. 1997; 336:1689–1696.

    Google Scholar 

  68. Ekre HP, Naparstek Y, Lider O, et al. Anti-inflammatory effects of heparin and its derivatives: inhibition of complement and of lymphocyte migration. In: Lane DA, ed. Heparin and Related Polysaccharides. New York: Plenum Press, 1992:329–340.

    Google Scholar 

  69. Lehmann K, Doris RJ, Feuer JM. Paradoxical increase in restenosis rate with chronic heparin use: final results of a randomized trial (abstr). J Am Coll Cardiol. 1991; 17:181A.

    Google Scholar 

  70. Ellis SG, Roubin GS, Wilentz J. Effect of 18-to 24-hour heparin administration for prevention of restenosis after complicated coronary angioplasty. Am Heart Journal. 1989; 117:777–782.

    CAS  Google Scholar 

  71. Caims JA, Gill J, Morton B, et al. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study. Circulation. 1996; 94:1553–1560.

    Google Scholar 

  72. Thornton MA, Gruentzig AR, Hollman J. Coumadin and aspirin in prevention of restenosis after transluminal coronary angioplasty: a randomized study. Circulation. 1984; 69.

    Google Scholar 

  73. Urban P, Buller N, Fox K. Lack of effect of warfarin on the restenosis or on clinical outcome after balloon coronary angioplasty. BMJ. 1988; 60:485–488.

    CAS  Google Scholar 

  74. Serruys PW, Herrman JP, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med. 1995; 333:757–763.

    PubMed  CAS  Google Scholar 

  75. Bittl JA, Strony J, Brinker JA. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med. 1995; 333:764–769.

    PubMed  CAS  Google Scholar 

  76. Yui Y, Kawai C, Hosoda S. Pravastatin (mevalotin) restenosis trial after percutaneous coronary angioplasty. Cholesterol reduction rate determines restenosis rate. Ann NY Acad Sci. 1995; 748:208–216.

    PubMed  CAS  Google Scholar 

  77. Knapp HR, Reilly IAG, Alessandrini P, et al. In vivo indices of platelet and vascular function during fish-oil administration in patients with atherosclerosis. N Engl J Med. 1986; 314:937–942.

    PubMed  CAS  Google Scholar 

  78. Davis HR, Bridenstine RT, Vesselinovitch D, et al. Fish oil inhibits development of atherosclerosis in rhesus monkeys. Arteriosclerosis. 1987; 7:441–449.

    PubMed  CAS  Google Scholar 

  79. Caims JA, Gill JB, Morton B. Enoxaprine and Maxepa for the prevention of angioplasty restenosis (EMPAR) (abstr). Circulation. 1994; 90:1–651.

    Google Scholar 

  80. Leaf A, Jorgensen MB, Jacobs AK, et al. Do fish oils prevent restenosis after coronary angioplasty? Circulation. 1994; 90:2248–2257.

    PubMed  CAS  Google Scholar 

  81. Rose TE, Beauchamp BG. Short term, high dose steroid treatment to prevent restenosis in PTCA (abstr). Circulation. 1987; 76:IV-371.

    Google Scholar 

  82. Pepine CJ, Hirshfeld JW, MacDonald RG. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. Circulation. 1990; 81:1753–1761.

    PubMed  CAS  Google Scholar 

  83. O’Keefe JHJ, McCallister BD, Bateman TM, et al. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol. 1992; 19:1597–1600.

    PubMed  Google Scholar 

  84. Eriksen UH, Amtorp O, Bagger JP, et al. Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty. Am Heart Journal. 1995; 130:1–8.

    CAS  Google Scholar 

  85. Maresta A, Balducelli M, Cantini L, et al. Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica. Circulation. 1994; 90:2710–2715.

    PubMed  CAS  Google Scholar 

  86. Okamoto S, Inden M, Setsuda M. Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. Am Heart Journal. 1992; 123:1439–1444.

    CAS  Google Scholar 

  87. Tanaka K, Honda M, Kuramochi T. Prominent inhibitory effects of tranilast on migration and proliferation of and collagen synthesis by vascular smooth muscle cells. Atherosclerosis. 1994; 107:179–185.

    PubMed  CAS  Google Scholar 

  88. Ueda K, Tamai H, Hsu YS. Effect of tranilast on restenosis after coronary angioplasty: Is there any rebound phenomenon after ceasing tranilast at 3 months? (abstr). J Am Coll Cardiol. 1995; 25:225A.

    Google Scholar 

  89. Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group [see comments]. N Engl J Med. 1997; 337:365–372.

    PubMed  CAS  Google Scholar 

  90. Rodes J, Cote G, Lesperance J, et al. Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation. 1998; 97:429–436.

    PubMed  CAS  Google Scholar 

  91. Libby P, Ganz P. Restenosis revisited-new targets, new therapies [editorial; comment]. N Engl J Med. 1997; 337:418–419.

    PubMed  CAS  Google Scholar 

  92. The ACCORD Study Investigators. Nitric oxide donors reduce restenosis after coronary angioplasty: The ACCORD Study (abstr). J Am Coll Cardiol. 1994; 23:59A.

    Google Scholar 

  93. Konneh MK, Rutherford C, Li SR, et al. Vitamin E inhibits the intimai response to balloon catheter injury in the carotid artery of the cholesterol-fed rat. Atherosclerosis. 1995; 113:29–39.

    PubMed  CAS  Google Scholar 

  94. Nunes GL, Sgoutas DS, Redden RA, et al. Combination of vitamins C and E alters the respoase to coronary balloon injury in the pig. Arterioscler Thromb Vasc Biol. 1995; 15:156–165.

    PubMed  CAS  Google Scholar 

  95. DeMaio SJ, King SBd, Lembo NJ, et al. Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transiuminal coronary angioplasty (PTCA). Journal of the American College of Nutrition. 1992; 11:68–73.

    PubMed  CAS  Google Scholar 

  96. Yang Z, Noll G, Luscher TF. Calcium antagonists differently inhibit proliferation of human coronary smooth muscle cells in response to pulsatile stretch and platelet-derived growth factor. Circulation. 1993; 88:932–936.

    Google Scholar 

  97. Ikeda Y, Kikuchi M, Toyama K, et al. Inhibition of human platelet functions by verapamil. Thrombosis and Hemostasis. 1981; 45:158–161.

    CAS  Google Scholar 

  98. Hillegass WB, Ohman EM, Leimberger JD, et al. A meta-analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplasty [see comments]. Am J Cardiol. 1994; 73:835–839.

    PubMed  CAS  Google Scholar 

  99. Powell JS, Glozel JP, Muller RK. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989; 245:186–188.

    PubMed  CAS  Google Scholar 

  100. Ribichini F, Steffenino G, Dellavalle A, et al. Plasma activity and insertion/deletion polymorphism of angioteasin 1-converting enzyme. Circulation. 1998; 97:147–154.

    PubMed  CAS  Google Scholar 

  101. Berger PB, Holmes DR, Jr., Ohman EM, et al. Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR). J Am Coll Cardiol. 1996; 27:1–7.

    PubMed  CAS  Google Scholar 

  102. Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol. 1995; 25:362–369.

    PubMed  CAS  Google Scholar 

  103. Hermans WR, Foley DP, Rensing BJ, et al. Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions—further evidence for the restenosis paradox. MERCATOR Study Group (Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis). Am Heart Journal. 1994; 127:483–494.

    CAS  Google Scholar 

  104. Gordon PC, Gibson CM, Cohen DJ, et al. Mechanisms of restenosis and redilation within coronary stents—quantitative angiographic assessment. J Am Coll Cardiol. 1993; 21:1166–1174.

    PubMed  CAS  Google Scholar 

  105. Reimers B, Moussa I, Akiyama T, et al. Long-term clinical follow-up after successful repeat percutaneous intervention for stent restenosis. J Am Coll Cardiol. 1997; 30:186–192.

    PubMed  CAS  Google Scholar 

  106. Bauters C, Banos J, Van Belle E, et al. Six-month angiographic outcome after successful repeat percutaneous intervention of in-stent restenosis. Circulation. 1998; 97:318–321.

    PubMed  CAS  Google Scholar 

  107. Serruys PW, Emanuelsson H, van der Giessen W, et al. Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. Circulation. 1996; 93:412–422.

    PubMed  CAS  Google Scholar 

  108. Condado JA, Gurdiel OG, Espinosa R, et al. Long-term angiographic and clinical outcome following balloon angioplasty and intracoronary radiation therapy in humans (abstract). Circulation. 1996; 94:1–209.

    Google Scholar 

  109. Carter AJ, Laird JR, Bailey LR, et al. Effects of endovascular radiation from a beta-particle-emitting stent in a porcine coronary restenosis model. A dose-response study [see comments]. Circulation. 1996; 94:2364–2368.

    PubMed  CAS  Google Scholar 

  110. Gajdusek CM, Tian H, London S, et al. Gamma radiation effect on vascular smooth muscle cells in culture. International Journal of Radiation Oncology, Biology, and Physics. 1996; 36:821–828.

    CAS  Google Scholar 

  111. Wiedermann JG, Leavy JA, Amols H, et al. Effects of high-dose intracoronary irradiation on vasomotor function and smooth muscle histopathology. American Journal of Physiology. 1994; 267:H125–H132.

    PubMed  CAS  Google Scholar 

  112. Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting [see comments]. N Engl J Med. 1997; 336:1697–1703.

    PubMed  CAS  Google Scholar 

  113. Hinohara T, Robertson GC, Simpson JB. Directional coronary atherectomy. In: Topol EJ, ed. Textbook of Interventional Cardiology. Vol. 1. Philadelphia: Saunders, 1994:641–658.

    Google Scholar 

  114. Adelman AG, Cohen EA, Kimball BP, et al. A comparison of directional atherectomy with balloon angioplasty for lesions of the left anterior descending coronary artery [see comments]. N Engl J Med. 1993; 329:228–233.

    PubMed  CAS  Google Scholar 

  115. Simonton CA, Leon MB, Kuntz RE. Acute and late clinical and angiographic results of directional atherectomy in the Optimal Atherectomy Restenosis Study (OARS) (abstr). Circulation. 1995; 92:1–545.

    Google Scholar 

  116. Simonton CA, Leon MB, Baim DS, et al. ‘Optimal’ directional coronary atherectomy: final results of the optimal atherectomy restenosis study (OARS). Circulation. 1998; 97:332–339.

    PubMed  CAS  Google Scholar 

  117. Baim DS, Cutlip DE, Sharma SK, et al. Final results of the balloon vs. optimal atherectomy trial (BOAT). Circulation. 1998; 97:322–331.

    PubMed  CAS  Google Scholar 

  118. Bertrand ME, Bauters C, Lablanche JM. Percutaneous coronary rotational angioplasty with the rotablator. In: Topol EJ, ed. Textbook of Interventional Cardiology. Vol. 1. Philadelphia: Saunders, 1994:659–667.

    Google Scholar 

  119. Strikwerda S, Montauban van Swijndregt E, Foley DP, et al. Immediate and late outcome of excimer laser and balloon coronary angioplasty: a quantitative angiographic comparison based on matched lesions. J Am Coll Cardiol. 1995; 26:939–946.

    PubMed  CAS  Google Scholar 

  120. Appelman YE, Piek JJ, Strikwerda S, et al. Randomised trial of excimer laser angioplasty versus balloon angioplasty for treatment of obstructive coronary artery disease [see comments]. Lancet. 1996; 347:79–84.

    PubMed  CAS  Google Scholar 

  121. Schofer J, Kresser J, Rau T, et al. Recanalization of chronic coronary artery occlusions using laser followed by balloon angioplasty [see comments]. Am J Cardiol. 1996; 78:836–838.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Interventional Cardiology Center, Columbia-Presbyterian Medical Center, Columbia University College of Physicians and Surgeons, New York, NY, USA

    Alan D. Simon M.D., Mark K. Warshofsky M.D. & Allan Schwartz M.D.

Authors
  1. Alan D. Simon M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark K. Warshofsky M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Allan Schwartz M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cardiology Division, Columbia University College of Physicians and Surgeons, New York, NY, USA

    LeRoy E. Rabbani M.D. (Assistant Professor of Medicine) (Assistant Professor of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Simon, A.D., Warshofsky, M.K., Schwartz, A. (1999). Restenosis: The Clinical Problem. In: Rabbani, L.E. (eds) Applications of Antisense Therapies to Restenosis. Perspectives in Antisense Science, vol 3. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5183-6_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5183-6_1

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7361-2

  • Online ISBN: 978-1-4615-5183-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation